2757 related articles for article (PubMed ID: 26621483)
41. Optimal management of ANCA-associated vasculitis before and during pregnancy: current perspectives.
Pecher AC; Henes M; Henes JC
Arch Gynecol Obstet; 2023 Aug; 308(2):379-385. PubMed ID: 36104505
[TBL] [Abstract][Full Text] [Related]
42. Antineutrophil cytoplasmic antibody-associated vasculitis classification by cluster analysis based on clinical phenotypes: a single-center retrospective cohort study.
Lee LE; Pyo JY; Ahn SS; Song JJ; Park YB; Lee SW
Clin Rheumatol; 2024 Jan; 43(1):367-376. PubMed ID: 37530864
[TBL] [Abstract][Full Text] [Related]
43. Anti-neutrophil cytoplasmic antibody specificity determines a different clinical subset in granulomatosis with polyangiitis.
Monti S; Felicetti M; Delvino P; Padoan R; Berti A; Paolazzi G; Brunori G; Schiavon F; Caporali R; Montecucco C
Clin Exp Rheumatol; 2021; 39 Suppl 129(2):107-113. PubMed ID: 34014158
[TBL] [Abstract][Full Text] [Related]
44. Characteristics and outcome of ANCA-associated vasculitides induced by anti-thyroid drugs: a multicentre retrospective case-control study.
Culerrier J; Nguyen Y; Karadag O; Yasar Bilge S; Yildrim TD; Ögüt TS; Yazisiz V; Bes C; Celfe A; Yazici A; Sadioglu Cagdas O; Kronbichler A; Jayne D; Gauckler P; Regent A; Teixeira V; Marchand-Adam S; Duffau P; Housz-Oro SI; Droumaguet C; Andre B; Luca L; Lechtman S; Aouba A; Lebas C; Servettaz A; Dernoncourt A; Ruivard M; Milesi AM; Poindron V; Jego P; Padoan R; Delvino P; Vandergheynst F; Pagnoux C; Yacyshyn E; Lamprecht P; Flossmann O; Puéchal X; Terrier B
Rheumatology (Oxford); 2024 Apr; 63(4):999-1006. PubMed ID: 37354498
[TBL] [Abstract][Full Text] [Related]
45. Treatment of Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Should Type of ANCA Guide the Treatment?
Tesar V; Hruskova Z
Clin J Am Soc Nephrol; 2020 Oct; 15(10):1519-1521. PubMed ID: 32471814
[No Abstract] [Full Text] [Related]
46. Performance of MPO-ANCA and PR3-ANCA immunoassays for the stratification of specific ANCA-associated vasculitis: A systematic review and meta-analysis.
Walker BS; Peterson LK; Koening C; White SK; Schmidt RL; Tebo AE
Autoimmun Rev; 2022 Jun; 21(6):103100. PubMed ID: 35452854
[TBL] [Abstract][Full Text] [Related]
47. Changes in proteinase 3 anti-neutrophil cytoplasm autoantibody levels in early systemic granulomatosis with polyangiitis (Wegener's) may reflect treatment rather than disease activity.
Rasmussen N; Salmela A; Ekstrand A; de Groot K; Gregorini G; Cohen Tervaert JW; Gross WL; Wiik A; Jayne DR;
Clin Exp Rheumatol; 2013; 31(1 Suppl 75):S38-44. PubMed ID: 23380137
[TBL] [Abstract][Full Text] [Related]
48. Clinical presentation and outcome prediction of clinical, serological, and histopathological classification schemes in ANCA-associated vasculitis with renal involvement.
Córdova-Sánchez BM; Mejía-Vilet JM; Morales-Buenrostro LE; Loyola-Rodríguez G; Uribe-Uribe NO; Correa-Rotter R
Clin Rheumatol; 2016 Jul; 35(7):1805-16. PubMed ID: 26852317
[TBL] [Abstract][Full Text] [Related]
49. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis.
Lionaki S; Blyth ER; Hogan SL; Hu Y; Senior BA; Jennette CE; Nachman PH; Jennette JC; Falk RJ
Arthritis Rheum; 2012 Oct; 64(10):3452-62. PubMed ID: 23023777
[TBL] [Abstract][Full Text] [Related]
50. Clinical significance of positive anti-neutrophil cytoplasmic antibodies without evidence of anti-neutrophil cytoplasmic antibodies-associated vasculitis.
Bornstein G; Ben-Zvi I; Furie N; Grossman C
Int J Rheum Dis; 2019 May; 22(5):940-945. PubMed ID: 30729688
[TBL] [Abstract][Full Text] [Related]
51. Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis.
Thompson GE; Fussner LA; Hummel AM; Schroeder DR; Silva F; Snyder MR; Langford CA; Merkel PA; Monach PA; Seo P; Spiera RF; St Clair EW; Stone JH; Specks U
Front Immunol; 2020; 11():2053. PubMed ID: 33013868
[No Abstract] [Full Text] [Related]
52. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update.
Hellmich B; Sanchez-Alamo B; Schirmer JH; Berti A; Blockmans D; Cid MC; Holle JU; Hollinger N; Karadag O; Kronbichler A; Little MA; Luqmani RA; Mahr A; Merkel PA; Mohammad AJ; Monti S; Mukhtyar CB; Musial J; Price-Kuehne F; Segelmark M; Teng YKO; Terrier B; Tomasson G; Vaglio A; Vassilopoulos D; Verhoeven P; Jayne D
Ann Rheum Dis; 2024 Jan; 83(1):30-47. PubMed ID: 36927642
[TBL] [Abstract][Full Text] [Related]
53. The performance of the chemiluminescent immunoassay for measuring serum myeloperoxidase and proteinase 3 antibodies.
Hou X; Liu J; Wang T; Zhou J; Cui L
J Clin Lab Anal; 2021 Feb; 35(2):e23615. PubMed ID: 33034910
[TBL] [Abstract][Full Text] [Related]
54. A population-based study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody (ANCA)-associated nephritis versus myeloperoxidase ANCA-associated nephritis.
Mohammad AJ; Segelmark M
J Rheumatol; 2014 Jul; 41(7):1366-73. PubMed ID: 24882836
[TBL] [Abstract][Full Text] [Related]
55. ANCA associated vasculitis (AAV): a review for internists.
Yaseen K; Mandell BF
Postgrad Med; 2023 Jan; 135(sup1):3-13. PubMed ID: 35831990
[TBL] [Abstract][Full Text] [Related]
56. Association of antineutrophil cytoplasmic antibody (ANCA) specificity with demographic and clinical characteristics of patients with ANCA‑associated vasculitides.
Wójcik K; Masiak A; Jeleniewicz R; Jakuszko K; Brzosko I; Storoniak H; Kur-Zalewska J; Wisłowska M; Madej M; Hawrot-Kawecka A; Głuszko P; Kucharz EJ;
Pol Arch Intern Med; 2022 Mar; 132(3):. PubMed ID: 34985235
[TBL] [Abstract][Full Text] [Related]
57. Genetics of ANCA-associated vasculitis: role in pathogenesis, classification and management.
Trivioli G; Marquez A; Martorana D; Tesi M; Kronbichler A; Lyons PA; Vaglio A
Nat Rev Rheumatol; 2022 Oct; 18(10):559-574. PubMed ID: 36109667
[TBL] [Abstract][Full Text] [Related]
58. Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited.
Bensalem A; Mulleman D; Paintaud G; Azzopardi N; Gouilleux-Gruart V; Cornec D; Specks U; Ternant D
Clin Pharmacokinet; 2020 Apr; 59(4):519-530. PubMed ID: 31586310
[TBL] [Abstract][Full Text] [Related]
59. ANCA-associated vasculitis: report from Korea.
Kim HW; Song YW
Clin Exp Nephrol; 2013 Oct; 17(5):708-711. PubMed ID: 23292177
[TBL] [Abstract][Full Text] [Related]
60. Proteinase 3-specific antineutrophil cytoplasmic antibody-associated vasculitis.
Falde SD; Fussner LA; Tazelaar HD; O'Brien EK; Lamprecht P; Konig MF; Specks U
Lancet Rheumatol; 2024 May; 6(5):e314-e327. PubMed ID: 38574742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
